Krensavage Asset Management, LLC
Krensavage Asset Management, LLC reported 18 US-listed holdings worth $263.2 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Enanta Pharmaceuticals Inc. (15.9%), Jazz Pharmaceuticals plc (15.4%) and United Therapeutics Corp. (14.3%). Against the quarter before, it opened 0 positions, added to 4, trimmed 2 and sold out of 2.
The 14 largest of its 18 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +74.9% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Added to 4
- Abbott Laboratories ABT+195,000 shares · +3900%
- Embecta Corp EMBC+400,000 shares · +54%
- Regeneron Pharmaceuticals, Inc. REGN+2,000 shares · +50%
- Ardelyx Inc. ARDX+34,523 shares · +7%
Trimmed 2
- United Therapeutics Corp. UTHR-15,000 shares · -18%
- Exelixis, Inc. EXEL-45,000 shares · -11%
Sold out of 2
- Indivior Pharmaceuticals, Inc. INDV$10.3 million last quarter
- Alkermes plc. ALKS$3.8 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Enanta Pharmaceuticals Inc. ENTA | 2.9M | $41.8 million | 15.88% | no change |
| Jazz Pharmaceuticals plc JAZZ | 167.8K | $40.4 million | 15.36% | no change |
| United Therapeutics Corp. UTHR | 69.3K | $37.5 million | 14.26% | -15.0K |
| Biomarin Pharmaceutical Inc. BMRN | 524.8K | $30.0 million | 11.41% | no change |
| Exelixis, Inc. EXEL | 370.7K | $20.2 million | 7.66% | -45.0K |
| Abbott Laboratories ABT | 200.0K | $18.1 million | 6.89% | +195.0K |
| Sanofi SNY | 323.9K | $13.8 million | 5.25% | no change |
| Supernus Pharmaceuticals, Inc. SUPN | 280.7K | $13.1 million | 4.96% | no change |
| Ultragenyx Pharmaceutical in RARE | 390.9K | $13.1 million | 4.96% | no change |
| Vanda Pharmaceuticals Inc. VNDA | 1.2M | $7.2 million | 2.74% | no change |
| BioNTech SE BNTX | 59.5K | $5.5 million | 2.10% | no change |
| GSK plc GSK | 96.7K | $5.1 million | 1.93% | no change |
| Biogen Inc. BIIB | 20.0K | $4.3 million | 1.64% | no change |
| Regeneron Pharmaceuticals, Inc. REGN | 6.0K | $3.7 million | 1.42% | +2.0K |
| Embecta Corp EMBC | 1.1M | $3.7 million | 1.41% | +400.0K |
| Ardelyx Inc. ARDX | 534.5K | $2.7 million | 1.04% | +34.5K |
| Inmode Ltd INMD | 120.9K | $1.8 million | 0.67% | no change |
| Evolus Inc. EOLS | 158.0K | $1.1 million | 0.42% | no change |